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Abstract
Background: The activation of signal transducer and activator of transcription 3 (Stat3) pathway correlates with tumor 
growth, survival, drug resistance and poor prognosis in osteosarcoma. To explore the potential therapeutic values of 
this pathway, we assessed both the expression and the activation of Stat3 pathway in several pairs of multidrug 
resistant (MDR) osteosarcoma cell lines, and tissues. To explore the potential therapeutic values of this pathway, we 
analyzed the ability of the synthetic oleanane triterpenoid, C-28 methyl ester of 2-cyano-3,12-dioxoolen-1,9-dien-28-
oic acid (CDDO-Me), to inhibit Stat3 expression and activation as well as its effects on doxorubicin sensitivity in 
osteosarcoma cells.
Methods: Expression of Stat3, phosphorylated Stat3 (pStat3) and Stat3 targeted proteins, including Bcl-XL, Survivin and 
MCL-1 were determined in drug sensitive and MDR osteosarcoma cell lines and tissues by Western blot analysis. The 
effect of CDDO-Me on osteosarcoma cell growth was evaluated by MTT and apoptosis by PARP cleavage assay and 
caspase-3/7 activity.
Results: Stat3 pathway was activated in osteosarcoma tissues and in MDR cell lines. CDDO-Me inhibited growth and 
induced apoptosis in osteosarcoma cell lines. Treatment with CDDO-Me significantly decreased the level of nuclear 
translocation and phosphorylation of Stat3. The inhibition of Stat3 pathway correlated with the suppression of the anti-
apoptotic Stat3 targeted genes Bcl-XL, survivin, and MCL-1. Furthermore, CDDO-Me increased the cytotoxic effects of 
doxorubicin in the MDR osteosarcoma cell lines.
Conclusions: Stat3 pathway is overexpressed in MDR osteosarcoma cells. CDDO-Me significantly inhibited Stat3 
phosphorylation, Stat3 nuclear translocation and induced apoptosis in osteosarcoma. This study provides the 
framework for the clinical evaluation of CDDO-Me, either as monotherapy or perhaps even more effectively in 
combination with doxorubicin to treat osteosarcoma and overcome drug resistance.
Background
Osteosarcoma is the most common malignant tumor of
bone, which mainly affects children and adolescents [1,2].
Current treatment of osteosarcoma consists of multi
agent chemotherapy and surgical resection[3]. The
advancement in intensive chemotherapy has significantly
improved the 5-year survival rate from 10% with surgery
alone to approximately 60-70% when combined with che-
motherapy [1-4]. Even so, for 20 years, survival rate has
not changed and nearly 30-40% of the patients still expe-
rience local recurrence or metastasis, possibly because of
development of multidrug resistance (MDR). Overcom-
ing drug resistance is one approach to improve the sur-
vival rate of osteosarcoma patients. The development of
drug resistance is associated with many events, such as
activation of transcription factors, overexpression of anti-
apoptotic proteins, and overexpression of multidrug
resistance gene 1 (MDR1) [5-8]. Successful management
of osteosarcoma might be greatly aided by the use of
novel agents that could overcome drug resistance.
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Signal Transducer and Activator of Transcription 3
(Stat3) is one of the transcription factors that play an
important role in tumor cell growth, survival, prolifera-
tion, differentiation, apoptosis, metastasis, angiogenesis
and drug resistance [9-17]. Stat3 is activated (phosphory-
lated) by Janus-activated kinase (JAK)-1 or JAK-2 in
response to interleukin-6 (IL-6) family of cytokines and
growth factors [18]. Stat3 then forms homodimers that
translocate to the cell nucleus and binds to promoters of
target genes, activating oncogenes such as c-myc and
cyclin D, and antiapoptotic proteins [19]. Constitutive
activation of Stat3 pathway has been found in many can-
cer cells including osteosarcoma [9-11,13,14,16,17,20].
Furthermore, constitutively activated Stat3 pathway cor-
relates with malignant tumor phenotype, resistance to
chemotherapeutic drugs, and poor prognosis in some
cancers [8,15,17,21-27].
Several reports have shown inhibition of Stat3 path-
ways in cancer cells, resulting in a dramatic increase of
apoptosis [13,17,20,28-32]. The novel synthetic oleanane
triterpenoid, C-28 methyl ester of 2-cyano-3,12-
dioxoolen-1,9-dien-28-oic acid (CDDO-Me), is a promis-
ing new class of agents for the prevention and treatment
of cancer [33-35]. When CDDO-Me is applied at low
concentrations, it demonstrated a variety of anti-inflam-
matory effects. At higher concentrations, the compound
inhibits cancer cell growth and proliferation in a wide
variety of cell lines including ovarian, cervical, breast,
liver, leukemia, and lung cancer [17,32-38]. CDDO-Me is
currently in phase I/II clinical trials for cancer treatment
[36-39]. CDDO-Me-induced apoptosis is associated with
the activation of caspase 3 and 8, cytochrome c, SOCS-1,
and SHP-1, and inhibition of NF-kB, Cox2 and VEGF
[32,33,35,40]. To date, the effect of CDDO-Me on MDR
osteosarcoma cells is unclear.
In this study, we investigated the molecular mechanism
of CDDO-Me induced apoptosis and the effects of com-
binations of CDDO-Me with doxorubicin which is
known to have established activity in the clinical therapy
for osteosarcoma.
Methods
Cell lines, tissues, antibodies and drugs
Human osteosarcoma cells KHOS, U-2OS, SaOS were
obtained from the American Type Tissue Collection
(Rockville, MD) and a normal human hipbone osteoblast
cell line HOB-c was obtained from the Promo Cell GmbH
(Heidelberg, Germany). The MDR cell line U-2OSTR was
established as previously reported [1,2]. Briefly, the U-
2OS cell lines were selected over a period of 8 months by
continuous culturing in medium containing step-wise
increases in drugs. Dr. Efstathios Gonos (Institute of Bio-
logical Research and Biotechnology, Athens, Greece)
kindly provided the MDR KHOSR2 cell line [41]. In addi-
tion, osteosarcoma tissue samples were obtained from the
Massachusetts General Hospital Sarcoma Tissue Bank.
Surgically treated patients diagnosed with osteosarcoma
were identified and utilized for the study and were used
in accordance with the policies of the Institutional
Review Board of the institution. Doxorubicin was
obtained through unused residual clinical material at the
Massachusetts General Hospital. CDDO-Me was kindly
provided by Dr. Jeff Supko (Massachusetts General Hos-
pital). The stock solution of drugs were prepared accord-
ing to the drug specifications and stored at -20°C. The
rabbit polyclonal antibodies to Stat3, Bcl-XL, MCL-1,
PARP, and the mouse monoclonal antibodies to phospho-
rylated Stat3 (pStat3), survivin were purchased from Cell
Signaling Technologies (Cambridge, MA). The mouse
monoclonal antibody to β-actin and MTT reagent were
purchased from Sigma-Aldrich (St. Louis, MO). The
Pgp1 monoclonal antibody C219 was purchased from
Signet (Dedham, MA). Goat antimouse-HRP and goat
antirabbit-HRP were purchased from BIO-Rad (Hercules,
CA). SuperSignal®  West Pico Chemiluminescent Sub-
strate was purchased from PIERCE (Rockford, IL).
Cell culture
Osteoblast cells HOB-c were cultured in Osteoblast
Growth Medium (Promo Cell), and all other cell lines
were cultured in RPMI 1640 supplemented with 10% fetal
bovine serum, 100 U/ml penicillin, and 100 μg/ml strep-
tomycin (all obtained from Invitrogen, Carlsbad, CA). All
cells were incubated at 37°C in 5% CO2-95% air atmo-
sphere and passaged when near confluent monolayers
were achieved using trypsin-EDTA solution. Resistant
cell lines were continuously cultured in 0.1 μM doxorubi-
cin. Cells were free of mycoplasma contamination as
tested by MycoAlert® Mycoplasma Detection Kit from
Cambrex (Rockland, ME).
Western blotting
Protein lysates from osteosarcoma cells and tissues were
generated through lysis with 1× radioimmunoprecipita-
tion assay lysis buffer (Upstate Biotechnology, Charlottes-
ville, VA). The concentration of the protein was analyzed
by DC Protein assay (Bio-Rad Laboratories, Hercules,
CA) and spectrophotometer (Beckman DU-640, Beck-
man Instruments, Inc., Columbia, MD). Thirty micro-
grams of total protein was processed on Nu-Page 4-12%
Bis-Tris Gel (Invitrogen) and transferred to a pure nitro-
cellulose membrane (Bio-Rad) then immunoblotted with
specific antibodies. Primary antibodies were incubated at
1:1000 dilution in Tris-buffered saline, pH 7.4, with 0.1%
Tween-20 and 5% nonfat milk (Bio-Rad) overnight at 4°C.
Horseradish peroxidase-conjugated secondary antibodies
(Bio-Rad) were incubated in Tris-buffered saline, pH 7.4,
with 0.1% Tween-20 and 5% nonfat milk, at 1:2,000 dilu-Ryu et al. BMC Cancer 2010, 10:187
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tions for 1 hour at room temperature. Positive immuno-
reactions were detected by using SuperSingal West Pico
Chemiluminescent Substrate (Pierce, Rockford, IL).
Cell viability analysis
The In vitro cell viability analysis was performed by MTT
assay as described previously [42]. For analyzing effects of
CDDO-Me on KHOS, KHOSR2, U-2OS, U-2OSTR and
HOB-c, 2 × 103 cells per well were plated in 96-well plates
in culture medium containing increasing concentrations
of CDDO-Me. For the effect of varying concentrations of
CDDO-Me on U-2OSTR and KHOSR2, 2 × 103 cells per
well were plated in 96-well plates in culture medium con-
taining increasing concentrations of doxorubicin and
CDDO-Me at final concentrations of 0.1 and 0.3 μmol/L,
respectively. After 7 days of culture at 37°C, 10 μl MTT (5
mg/ml in PBS, obtained from Sigma) was added to each
well and the plates were incubated for 3 h. The resulting
formazan product was dissolved with acid-iso-propanol
and the absorbance at a wavelength of 490 nm (A490) was
read on a SPECTRAmax Microplate Spectrophotometer
(Molecular Devices, Sunnyvale, CA). The absorbance val-
ues were normalized by assigning the value of the control
line in the medium without drug to 1.0 and the value of
the no cell control to 0. Experiments were performed in
triplicate. The half inhibitory concentration (IC50) was
defined as the compound or chemo drug concentration
required decreasing the A490 to 50% of the control value.
Apoptosis assay
Lysates from whole-cell were immunoblotted with spe-
cific antibodies to PARP (Cell Signaling Technology) and
its cleavage products. Positive immunoreactions were
detected by using Super Signal West Pico Chemilumines-
cent Substrate. As a second parameter of apoptotic cell
death, we measured caspase-3/7 activities in HOB-c,
KHOS and KHOSR2 after treatment with CDDO-Me by
using Apo-ONE Homogenous caspase-3/7 system
according to the manufacturer's instructions (Promega,
Madison, WI). The intensity of the emitted fluorescence
was determined at a wavelength of 521 nm with the use of
a SPECTRAmax® Microplate Spectrofluorometer (Molec-
ular Devices).
Real-time analysis of the effect of CDDO-Me on Stat3 
nucleocytoplasmic translocation
To study the effects of CDDO-Me on Stat3 nuclear trans-
location in live cells, a real-time cell based assay was used
as described below. Stable transfectants expressing
EGFP-Stat3 were generated with the osteosarcoma cell
line U-2OS using standard lipofectmine transfection
techniques with G418 selection. EGFP-Stat3 expressing
cells were seeded at a density of 4 × 103 cells per well in 96
well plates and incubated overnight at 37°C. The cells
were then treated with either 1 μM CDDO-Me with 30
ng/ml human recombinant IL-6 (R&D Systems, Minne-
apolis, MN) or IL-6 alone. To counterstain the nuclei, the
cells were incubated with 1 μg/ml Hoechst 33342 (Invit-
rogen, Carlsbad, CA) for 1 minute. IL-6 dependent
nuclear translocation of EFGP-Stat3 was analyzed using
an Olympus 1X71 fluorescence microscope and the pic-
tures were captured as digital images using IPLab Soft-
ware from Scanalytics (Rockville, MD).
Data analysis
Values shown are representative of triplicate determina-
tions in two or more experiments. The IC50 was calcu-
lated and the effects of treatment were evaluated using a
two-sided Student's t test (GraphPad PRISM® 4 software,
GraphPad Software, San Diego, CA). Errors are a SD
(standard deviation) of averaged results and with value p
< 0.05 was considered as a significant difference between
means.
The combination index (CI) for experimental treatment
combinations was calculated to determine the synergis-
tic, additive, or antagonistic effects using the Chou-Tala-
lay method and GraphPad PRISM® 4 software[43]. When
CI = 1, the equation represents the conservation isobolo-
gram and indicates additive effects. CI values of <1.0 indi-
cates synergistic effect, > 1.0 indicates antagonistic effect.
Results
Stat3 pathway is activated in osteosarcoma cell lines and 
tissues
To evaluate the expression and activation of Stat3 path-
way, we analyzed the protein expression in several pairs
of both drug sensitive and MDR osteosarcoma cell lines
and 8 samples of osteosarcoma tissues. Western blot
analysis demonstrated that Stat3 and pStat3 were consti-
tutively overexpressed in drug sensitive cell lines KHOS,
U-2OS, SaOS and MDR cell lines KHOSR2, U-2OSTR.
Normal osteoblast cell line HOB-c expressed Stat3 as well
as low levels of pStat3 (Fig. 1A). In osteosarcoma tissues,
Stat3 was overexpressed in all of the samples and pStat3
was overexpressed in 7 out of 8 (88%) samples (Fig. 1B).
Following this preliminary study, we analyzed the expres-
sion of Stat3-mediated antiapoptotic proteins Bcl-XL,
survivin, and MCL-1. Western blot analysis demon-
strated that Bcl-XL, survivin, and MCL-1 were constitu-
tively overexpressed in drug sensitive cell lines and MDR
osteosarcoma cell lines. Osteoblast cell lines HOB-c con-
trols showed no expression of Stat3-mediated anti-apop-
totic proteins. Pgp1 is also over expressed in MDR cell
lines (Fig. 1A). Osteosarcoma tissues showed heteroge-
neous expression of Stat3 mediated antiapoptotic pro-
teins and Pgp1 (Fig. 1B).Ryu et al. BMC Cancer 2010, 10:187
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CDDO-Me inhibits growth and induces apoptosis in 
osteosarcoma cells
To confirm that CDDO-Me inhibits cell growth, KHOS,
U-2OS, KHOSR2, U-2OSTR, and HOB-c were evaluated
using MTT assay. The results showed that the growth of
all cell lines was inhibited after treatment with CDDO-
Me (Fig. 2A). CDDO-Me showed significantly higher
antiproliferative activity in osteosarcoma cells than in
osteoblast cells (p < 0.0001). The IC50 of each cells were
HOB-c: 0.8 μM, KHOS: 0.15 μM, KHOSR2: 0.33 μM, U-
2OS: 0.17, U-2OSTR: 0.39 μM. The effect of CDDO-Me
on the induction of apoptosis was assessed by evaluating
PARP cleavage and caspase assay for both drug sensitive
and MDR osteosarcoma cell lines. PARP cleavage was
detected in all cells after 24 hours of treatment with
CDDO-Me. A dose-response analysis revealed the
appearance of PARP cleavage products in the presence of
0.5 μmol/L of CDDO-Me for KHOS, KHOSR2 and 1.0
μmol/L of CDDO-Me for U-2OS, U-2OSTR (Fig. 2B). In
addition, caspase-3/7 activity was significantly increased
when KHOS and KHOSR2 were treated with increasing
concentration of CDDO-Me (Fig. 3).
CDDO-Me inhibits IL-6 induced nuclear translocation of 
Stat3
To identify the interruption of IL-6 dependent Stat3
nuclear translocation by CDDO-Me, a novel real-time
cell-based method was developed to image the EGFP-
Stat3 chimera in the nucleus and cytoplasm in human
osteosarcoma cell line U-2OS. Resting cells demonstrated
that the majority of EGFP-Stat3 was cytoplasmic (Fig. 4A,
A') until the addition of IL-6, which then promptly
induced translocation of fluorescent Stat3 to the nucleus
in U-2OS cells (Fig. 4B). Pretreatment of the cells with
CDDO-Me (1 μM) blocked IL-6 dependent EGFP-Stat3
nuclear translocation (Fig. 4B').
Figure 1 Activation of Stat3, pStat3, Stat3-mediated antiapoptotic proteins, and Pgp1 in osteosarcoma cell lines and tissues. A) Osteoblast 
cell lines, drug sensitive and MDR osteosarcoma cell lines. B) Osteosarcoma tissues. Expression was assessed with total cellular protein isolated from 
the indicated cell lines and immunoblotted with specific antibodies as described in Materials and Methods. The blots were also probed with an anti-
actin monoclonal antibody to assess relative protein levels in the sample lanes.Ryu et al. BMC Cancer 2010, 10:187
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CDDO-Me inhibits Stat3 pathway in a dose-dependent 
manner
After identifying CDDO-Me as an inhibitor of Stat3
nuclear translocation in osteosarcoma cells, the effect of
CDDO-Me on Stat3 phosphorylation was examined in
osteosarcoma drug sensitive and MDR cell lines. To eval-
uate the dose-dependent inhibition of Stat3 activation,
the cell lines were treated with CDDO-Me alternatively
with varying doses for 24 h. In a dose-dependent manner,
concentrations as low as 0.5 μM CDDO-Me inhibited
Stat3 phosphorylation (Fig. 5). Stat3 phosphorylation and
nuclear translocation are required for Stat3 transcrip-
tional activity. We hypothesized that inhibition of nuclear
transport should suppress transcription and subsequent
translation of Stat3-mediated proteins. Therefore, we
next examined whether exposure of cell lines to CDDO-
Me resulted in decreased expression of the antiapoptotic
proteins Bcl-XL, survivin and MCL-1 by dose-dependent
inhibition (Fig. 5). Results showed incubation of CDDO-
Me for 24 h caused significant down-regulated Bcl-XL,
survivin and MCL-1 expression in both drug sensitive
Figure 2 CDDO-Me inhibits growth and induces apoptosis in osteosarcoma cell lines. A) To analyze the effect of CDDO-Me, KHOS, U-2OS, 
KHOSR2, U-2OSTR, and HOB-c were exposed to varying concentrations of CDDO-Me for 7 days. Growth inhibition was assessed by MTT. B) Parental cells 
KHOS, U-2OS and MDR cells KHOSR2 and U-2OSTR were treated with CDDO-Me in a dose-dependent manner. Total cellular proteins were subjected to 
immunoblotting with specific antibodies to PARP and β-actin. PARP cleavage was detected in all four osteosarcoma cell lines after treatment with 
CDDO-Me. The anti-PARP antibodies demonstrate 118 kd full length PARP and 85 kd cleaved PARP fragment.
Figure 3 Caspase-3/7 activity was measured as a second parame-
ter of apoptotic cell death. KHOS and KHOSR2 showed significant in-
crease in apoptosis when they were treated with increasing 
concentrations of CDDO-Me. The experiment was repeated three 
times in triplicate.Ryu et al. BMC Cancer 2010, 10:187
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(Fig. 5A) and MDR (Fig. 5B) cell lines in a dose-depen-
dent manner.
CDDO-Me inhibits Stat3 pathway and induces apoptosis in 
a time-dependent manner
To evaluate the time-dependent inhibition of Stat3 acti-
vation, the cell lines were treated with 1 μM of CDDO-
Me for varying time periods for 24 h. In a time-depen-
dent manner, the pStat3 level decreased as early as 4
hours after the addition of 1 μM of CDDO-Me treatment
(Fig. 6). We next examined whether exposure of cell lines
to CDDO-Me resulted in decreased expression of the
antiapoptotic proteins Bcl-XL, survivin and MCL-1 by
time-dependent inhibition (Fig. 6). Results showed incu-
bation of CDDO-Me for 24 h caused significant down-
regulation of Bcl-XL, survivin and MCL-1 expression in
both drug sensitive (Fig. 6A) and MDR (Fig. 6B) cell lines
in a time dependent manner. The effect of CDDO-Me on
the induction of apoptosis was assessed by evaluating
PARP cleavage in a time-dependent manner. PARP cleav-
age was detected in all cells after 12 hours of treatment
with 1 μM of CDDO-Me (Fig. 6).
CDDO-Me has no effect on Pgp-1 expression
While CDDO-Me significantly inhibits Stat3 phosphory-
lation in KHOSR2, U-2OSTRcells, there was no significant
change in Pgp1 expression as observed in the Pgp1-over
expressing cell lines (Fig. 5B and 6B).
CDDO-Me shows synergy with doxorubicin and reduces 
resistance in MDR osteosarcoma cell lines
To examine whether interruption of the Stat3 pathway
shows synergistic effect when combined with chemother-
apy, we analyzed the effect of CDDO-Me in the presence
or absence of doxorubicin. Treatment of MDR cell lines
with doxorubicin, CDDO-Me or combination of both
drugs were analyzed using MTT. The combination of the
two agents doxorubicin and CDDO-Me resulted in sig-
nificantly greater cell death than either drug alone (Fig
7A). The combination index (CI) values were <1 in all
cases and thereby identified synergistic interaction at all
combinations between CDDO-Me and doxorubicin at
various combination. The CI of each combinations were
KHOSR2/doxorubicin+CDDO-Me(0.1 μM): 0.98,
KHOSR2/doxorubicin+CDDO-Me(0.3 μM): 0.64, U-
2OSTR/doxorubicin+CDDO-Me(0.1 μM): 0.83, U-2OSTR/
doxorubicin+CDDO-Me(0.3 μM): 0.51.
To investigate the inhibition of Stat3 pathway's effect
on drug sensitive osteosarcoma cell lines KHOS, U-2OS
and MDR osteosarcoma cell lines KHOSR2, U-2OSTR,
they were exposed to varying concentrations of doxorubi-
cin and CDDO-Me for 7 days. MTT demonstrated that
Figure 4 CDDO-Me inhibits EGFP-Stat3 nuclear translocation in osteosarcoma cell line U-2OS. U-2OS cells which stably express the EGFP-Stat3 
fusion protein were incubated for 4 h with either IL-6 alone (A-D) or CDDO-Me (1 μM) followed immediately thereafter with the addition of IL-6 to a 
final concentration of 30 ng/ml (A'-D'). To counterstain the nuclei, the cells were incubated with 1 μg/ml Hoechst 33342 (Invitrogen, Carlsbad, CA) for 
1 minute. Cells were photographed 1 h later. Subcellular localization of the fusion protein was assessed by fluorescence microscopy.Ryu et al. BMC Cancer 2010, 10:187
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CDDO-Me has a synergistic effect on doxorubicin-
induced antiproliferative effect in KHOSR2 and U-2OSTR
(Fig 7B and 7C). In addition, MTT assay demonstrated
that CDDO-Me increases doxorubicin's effect and par-
tially overcomes doxorubicin-resistance. The IC50 of each
cells were KHOS: 0.07 μM, KHOSR2/CDDO-Me(0.3 μM):
0.11 μM, KHOSR2/CDDO-Me(0.1 μM): 0.29 μM,
KHOSR2: 0.86 μM (Fig 6B), and U-2OS: 0.06 μM, U-
2OSTR/CDDO-Me(0.3 μM) 0.12 μM, U-2OSTR/CDDO-
Me(0.1 μM): 0.24 μM, U-2OSTR: 0.93 μM (Fig 7C).
Discussion
Stat3 pathway plays an important role in tumor cell
growth and proliferation, and is constantly activated in
many human cancer cell lines and tumor tissues [9-
14,17,20]. Constitutive activation of Stat3 pathway could
be an early indicator of drug resistance[15]. Activation of
Stat3 pathway was also reported to be present in osteo-
sarcoma cells and tissues [14,20]. In this study, we
observed that elevated levels of Stat3 and pStat3 are
detected in osteosarcoma drug sensitive cell lines KHOS,
U-2OS, SaOS and osteosarcoma MDR cell lines KHOSR2,
U-2OSTR.  T h e  d a t a  i s  c o n s i s t e n t  w i t h  p r ev i o u s  s t u d i e s
that Stat3 pathways play an important role in not only
drug sensitive but also drug resistant osteosarcoma cells
[14,20]. The downstream effect of Stat3 activation is the
Stat3-dependent regulation of several antiapoptotic genes
including Bcl-XL, survivin, and MCL-1. Overexpressions
of these survival-promoting genes have been shown to be
highly expressed and prevent apoptosis in human cancer
cells, especially in high-grade tumors [13,44-46]. In our
study, these antiapoptotic genes were highly expressed in
both drug sensitive and resistant osteosarcoma cell lines,
but not in normal human osteoblast cells.
Nuclear translocation of pStat3 is a crucial event for its
transcriptional function. Blocking the phosphorylation
and translocation of Stat3 is a rational approach for the
Figure 5 Dose-dependent inhibition of Stat3 phosphorylation and down-regulated Stat3-mediated antiapoptotic proteins by CDDO-Me. 
Parental cells KHOS, U-2OS (A) and MDR cells KHOSR2, U-2OSTR (B) were treated with CDDDO-Me for 24 hours in and then harvested and processed for 
Western blotting. For Western blot analysis, 30 μg of total cellular proteins were subjected to immunoblotting with specific antibodies.Ryu et al. BMC Cancer 2010, 10:187
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inhibition of Stat3 activation. Recently, Stat3 has been
implicated as a promising target for cancer therapy
[12,13,20,28-31]. Stat3 inhibitors, SD-1029 and SD-1008,
greatly induce apoptosis in drug resistant ovarian cancer
cells by blocking Stat3 nuclear translocation [29,30].
Stat3, pStat3 and Stat3 targeted antiapoptotic proteins
are over expressed in drug resistance osteosarcoma cells.
Inhibition of the Stat3 pathway and interruption of anti-
apoptotic response may also play an important role for
treatment of these cells. Our result is consistent with
recent reports showing that the novel Stat3 inhibitor,
Indirubin, significantly induces apoptosis in human
breast cancer cells [13]. In addition, LLL3, Stat3 DNA
binding and transcription activities inhibitor, and Stat3
siRNA significantly decrease cell proliferation and viabil-
ity, ultimately inducing apoptosis in osteosarcoma
cells[20].
CDDO is widely used in Asian herbal medicine and was
originally identified as an active compound for anti-
inflammatory and anti-carcinogenic treatments [34,39].
The novel compound CDDO-Me has been shown to be
highly effective in vivo models for the prevention and
treatment of cancer [33-35]. CDDO-Me is able to induce
the differentiation of tumor cells, suppress the growth of
tumor cells, and induce apoptosis in cancer cells that are
resistant to conventional chemotherapeutic agents [32].
Recent report has shown that CDDO-Me inhibits activa-
tion of the JAK/Stat3 pathway by forming adducts with
both JAK1 and Stat3 in human cervical and breast cancer
cells [34]. Previously, we also demonstrated that CDDO-
Me inhibits Stat3 pathway in ovarian cancer cells by
down-regulation of antiapoptotic genetic expression, and
resulted in a dramatic induction of apoptosis [17]. Fur-
thermore, recent study showed that the novel Stat3 target
gene Bcl-XL  inhibitor, ABT-737, greatly enhanced the
activities of paclitaxel in lung cancer cells [47]. In this
study, CDDO-Me inhibits Stat3 phosphorylation and
down-regulates Stat3-mediated antiapoptotic proteins
Bcl-XL, survivin and, MCL-1, in both dose and time
dependent manner. This was through apoptotic cell death
Figure 6 Time-dependent inhibition of Stat3 phosphorylation and down-regulated Stat3-mediated antiapoptotic proteins by CDDO-Me. 
Parental cells KHOS, U-2OS (A) and MDR cells KHOSR2, U-2OSTR (B) were treated for 24 h with CDDO-Me (1 μM), and then harvested and processed for 
Western blotting. For Western blot analysis, 30 μg of total cellular proteins were subjected to immunoblotting with specific antibodies.Ryu et al. BMC Cancer 2010, 10:187
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in both drug sensitive and resistant osteosarcoma cells.
Furthermore, the apoptotic threshold also increases the
sensitivity of these cells to the cytotoxic effects of doxoru-
bicin. The results are consistent with a series of studies
showing that CDDO-related compounds are not mono-
functional drugs that strictly target single steps in signal
transduction pathways [32,40,48]. Biochemical and cellu-
lar assays support the hypothesis that the molecule
CDDO-Me inhibits Stat3 activity with resultant inhibi-
tion of Stat3 phosphorylation, nuclear translocation, and
decrease in Stat3-dependent transcription, leading to
apoptosis and enhanced chemosensitivity.
Conclusion
Our results demonstrated that Stat3 pathways were con-
stantly activated in osteosarcoma and MDR osteosar-
coma cells. CDDO-Me significantly inhibits Stat3
phosphorylation and consequently Stat3 nuclear translo-
cation, and eventually resulted in inducing apoptosis in
these cells. In addition, this compound is able to over-
come drug resistance in these cells.
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